|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | lsolation of cells from ovine fetal long bone and characterization of their osteoblastic antivities during in vitro mineralization显示文摘 | Collignon H Davicco M J Barlet J P | 1997 | Arch Physiol Biochem1997，105，2： | 1 |
| 2 | Re- view of the current methods of analytical traceability allo- wing determination of the origin of foodstuffs 显示文摘 | Bruno Peres Nicolas Barlet Gerard Loiseau | 2007 | Food Control2007，18，： | 1 |
| 3 | Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘 | Collignon H Davicco MJ Barlet JP | 1997 | Arch Physiol Biochem1997，105，2： | 1 |
| 4 | Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘 | Collignon H Davicco MJ Barlet JP | 1997 | Arch Physiol Biochem1997，105，2： | 1 |
| 5 | Different prevalence of precore mutants in five members of a hepatitis-B-virus-infected family:evidence for a precore variant type in an asymptomatic anti-HBs patient显示文摘 | Barlet V Zarski JP Thelu MA | 1994 | J Hepatol1994，21，5： | 1 |
| 6 | lsolation of cells from oxine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘 | Collignon H Davicco MJ Barlet JP | 1997 | Arch Physiol Biochem1997，105，2： | 1 |
| 7 | Comparison of the ana- lytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201 显示文摘 | Assal A Barlet V Deschaseaux M | 2009 | Transfusion2009，49，2： | 1 |
| 8 | Review of the current methods of analytical traceability allowing determination of the origin of foodstuffs显示文摘 | Peres B Barlet N Loiseau G | 2007 | Food control2007，18，3： | 1 |
| 9 | Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘 | Collignon H Davicco M J Barlet JP | 1997 | Arch Physiol Biochem1997，105，2： | 1 |
| 10 | Apphcation of molecular biology to blood transfusion safety: the nucleic acid testing显示文摘 | Assal A Coste J Barlet V | 2003 | Transfus Clin Biol2003，10，3： | 1 |
| 11 | Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘 | Collignon H Davicco M J Barlet J P | 1997 | Arch PhysiolBiochem1997，105，2： | 1 |
| 12 | Application of molecular biology to blood transfusion safety: the nucleic acid testing显示文摘 | Assal A Coste J Barlet V | 2003 | Transfus Clin Biol2003，10，3： | 1 |
| 13 | Failure and Success of HIV Tests for the Prevention if HIV-1 Transmission by Blood and Tissue Donations显示文摘 | Fatiha Najioullah Valerie Barlet Philippe Renaudia | 2004 | Journal of Medical Virology2004，73，3： | 1 |
| 14 | FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer显示文摘AIM To evaluate the efficacy and safety of the modified FOLFIRI3-aflibercept as second-line therapy in patients with metastatic colorectal cancer.METHODS This is a retrospective multicenter cohort, evaluating the efficacy and safety of the association of aflibercept with FOLFIRI3(day 1: aflibercept 4 mg/kg, folinic acid 400 mg/m^2, irinotecan 90 mg/m^2, 5-fluorouracil infusion 2400 mg/m^2 per 46 h; day 3: irinotecan 90 mg/m^2) in patients with previously treated metastatic colorectal cancer. The primary endpoint was overall response rate(ORR). Secondary endpoints were disease control rate(DCR), progression-free survival(PFS), overall survival(OS), and safety.RESULTS Among 74 patients treated in four French centers, nine were excluded due to prior use of aflibercept(n = 3), more than one prior treatment line in irinotecanna?ve patients(n = 3), and inadequate liver function(n = 3). In the 'irinotecan-na?ve' patients(n = 30), ORR was 43.3% and DCR was 76.7%. Median PFS and OS were 11.3 mo(95%CI: 6.1-29.0) and 17.0 mo(95%CI: 13.0-17.3), respectively. The most common(> 5%) grade 3-4 adverse events were diarrhea(37.9%), neutropenia(14.3%), stomatitis and anemia(10.4%), and hypertension(6.7%). In the 'pre-exposed irinotecan' patients(n = 35), 20(57.1%) received ≥ 2 prior lines of treatment. ORR was 34.3% and DCR was 60.0%. Median PFS and OS were 5.7 mo(95%CI: 3.9-10.4) and 14.3 mo(95%CI: 12.8-19.5), respectively.CONCLUSION Minimally modified FOLFIRI has improvement dramatically the FOLFIRI3-aflibercept efficacy, whatever prior use of irinotecan. A prospective randomized trial is warranted to compare FOLFIRI-aflibercept to FOLFIRI3-aflibercept. | CANDice Carola Fran?ois Ghiringhelli Stefano Kim Thierry ANDré Juliette Barlet Le?la Bengrine-Lefevre Hélène Marijon Marie-Line Garcia-Larnicol Christophe Borg Linda Dainese Nils Steuer Hubert Richa Magdalena Benetkiewicz Annette K Larsen Aimery de Gramont Benoist Chibaudel | 2018 | World Journal of Clinical Oncology2018，9，5： | 1 |
| 15 | Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization 显示文摘 | Collignon H Davicco M J Barlet JP | 1997 | Arch Physiol Biochem1997，105，2： | 1 |
| 16 | Heterogeneous porosity distribution in portland cement exposed to CO2- rich fluids 显示文摘 | GAETAN RIMMELE VERONIQUE BARLET GOUEDARD OLIVIER PORCHERIE | 2008 | Cement and Concrete Research2008，38，8： | 1 |
| 17 | Effect of chronic ozone exposure on lung elasticity in young rats显示文摘 | Barlet D Faulkner C S Cook K | 1974 | Journal of Applied Physiology1974，37，： | 1 |
| 18 | Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization 显示文摘 | Collignon H Davicco M J Barlet J P | 1997 | Arch Physiol Biochem1997，105，2： | 1 |
| 19 | Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘 | Colliguon H Davicco MJ Barlet JP | 1997 | Arch Physiol Biochcm1997，105，2： | 1 |
| 20 | Isolation of cells from ovine fetal long bone and characterization of their osteoblastic activities during in vitro mineralization显示文摘 | COLLIGNON H DAVICCO M J BARLET J P | 1997 | Arch Physiod Biochem1997，105，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员